Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 244

1.

Proteomic characterization of chromosomal common fragile site (CFS)-associated proteins uncovers ATRX as a regulator of CFS stability.

Pladevall-Morera D, Munk S, Ingham A, Garribba L, Albers E, Liu Y, Olsen JV, Lopez-Contreras AJ.

Nucleic Acids Res. 2019 Sep 5;47(15):8004-8018. doi: 10.1093/nar/gkz510. Erratum in: Nucleic Acids Res. 2019 Sep 5;47(15):8332.

2.

ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.

Burford C, Laxton R, Sidhu Z, Aizpurua M, King A, Bodi I, Ashkan K, Al-Sarraj S.

Br J Neurosurg. 2019 Oct;33(5):536-540. doi: 10.1080/02688697.2019.1600657. Epub 2019 Apr 24.

PMID:
31018710
3.

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.

Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, Huse JT.

Nat Commun. 2019 Feb 26;10(1):943. doi: 10.1038/s41467-019-08905-8.

4.

ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features.

Olar A, Tran D, Mehta VP, Reinhardt A, Manekia JH, Garnovskaya M, Ellezam B, Luthra R, Sulman EP, Mohila CA, Campbell GA, Powell SZ, Fuller GN, Aldape KD, Adesina AM.

Clin Neuropathol. 2019 Mar/Apr;38(2):59-73. doi: 10.5414/NP301105.

PMID:
30499772
5.

ATRX promotes maintenance of herpes simplex virus heterochromatin during chromatin stress.

Cabral JM, Oh HS, Knipe DM.

Elife. 2018 Nov 22;7. pii: e40228. doi: 10.7554/eLife.40228.

6.

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.

Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK.

PLoS One. 2018 Sep 18;13(9):e0204159. doi: 10.1371/journal.pone.0204159. eCollection 2018.

7.

ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.

Chou A, Itchins M, de Reuver PR, Arena J, Clarkson A, Sheen A, Sioson L, Cheung V, Perren A, Nahm C, Mittal A, Samra JS, Pajic M, Gill AJ.

Hum Pathol. 2018 Dec;82:249-257. doi: 10.1016/j.humpath.2018.07.032. Epub 2018 Aug 3.

8.

Mutant ATRX: uncovering a new therapeutic target for glioma.

Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein PR, Castro MG.

Expert Opin Ther Targets. 2018 Jul;22(7):599-613. doi: 10.1080/14728222.2018.1487953. Epub 2018 Jun 20. Review.

9.

A metadynamic approach to understand the recognition mechanism of the histone H3 tail with the ATRXADD domain.

Dash RC, Zaino AM, Hadden MK.

Biochim Biophys Acta Gene Regul Mech. 2018 Jun;1861(6):594-602. doi: 10.1016/j.bbagrm.2018.05.001. Epub 2018 May 3.

PMID:
29730439
10.

Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.

Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A.

Brain Tumor Pathol. 2018 Apr;35(2):106-113. doi: 10.1007/s10014-018-0312-5. Epub 2018 Mar 17.

PMID:
29550880
11.

Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature.

Li Y, Liu X, Qian Z, Sun Z, Xu K, Wang K, Fan X, Zhang Z, Li S, Wang Y, Jiang T.

Eur Radiol. 2018 Jul;28(7):2960-2968. doi: 10.1007/s00330-017-5267-0. Epub 2018 Feb 5.

PMID:
29404769
12.

ATRX is a regulator of therapy induced senescence in human cells.

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A.

Nat Commun. 2017 Aug 30;8(1):386. doi: 10.1038/s41467-017-00540-5.

13.

The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats.

Nguyen DT, Voon HPJ, Xella B, Scott C, Clynes D, Babbs C, Ayyub H, Kerry J, Sharpe JA, Sloane-Stanley JA, Butler S, Fisher CA, Gray NE, Jenuwein T, Higgs DR, Gibbons RJ.

EMBO Rep. 2017 Jun;18(6):914-928. doi: 10.15252/embr.201643078. Epub 2017 May 9.

14.

Inherited germline ATRX mutation in two brothers with ATR-X syndrome and osteosarcoma.

Ji J, Quindipan C, Parham D, Shen L, Ruble D, Bootwalla M, Maglinte DT, Gai X, Saitta SC, Biegel JA, Mascarenhas L.

Am J Med Genet A. 2017 May;173(5):1390-1395. doi: 10.1002/ajmg.a.38184. Epub 2017 Mar 28.

PMID:
28371217
15.

Deciphering the Molecular Effects of Mutations on ATRX Cause ATRX Syndrome: A Molecular Dynamics Study.

Palaniappan C, Ramalingam R.

J Cell Biochem. 2017 Oct;118(10):3318-3327. doi: 10.1002/jcb.25984. Epub 2017 May 3.

PMID:
28294389
16.

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D.

J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28.

PMID:
27796734
17.

Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.

Ogasawara S, Fujii Y, Kaneko MK, Oki H, Sabit H, Nakada M, Suzuki H, Ichimura K, Komori T, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2016 Oct;35(5):254-258.

18.

Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas.

Rodriguez FJ, Vizcaino MA, Blakeley J, Heaphy CM.

Acta Neuropathol. 2016 Nov;132(5):761-763. Epub 2016 Sep 20. No abstract available.

PMID:
27650176
19.

ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.

Kakkar A, Nambirajan A, Kaur K, Kumar A, Mallick S, Suri V, Sarkar C, Kale SS, Garg A, Sharma MC.

J Neurooncol. 2016 Oct;130(1):63-68. Epub 2016 Jul 28.

PMID:
27469217
20.

ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset.

Purkait S, Miller CA, Kumar A, Sharma V, Pathak P, Jha P, Sharma MC, Suri V, Suri A, Sharma BS, Fulton RS, Kale SS, Dahiya S, Sarkar C.

Brain Pathol. 2017 Mar;27(2):138-145. doi: 10.1111/bpa.12364. Epub 2016 Jun 13.

PMID:
26833422

Supplemental Content

Support Center